Internal medicine (Tokyo, Japan) · 2007
Effectiveness of subcutaneous growth hormone in HIV-1 patients with moderate to severe facial lipoatrophy.
Клиническое исследованиеСтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Honda Miwako, Yogi Akira, Ishizuka Naoki, Genka Ikumi, Gatanaga Hiroyuki, Teruya Katsuji, Tachikawa Natsuo, Kikuchi Yoshimi, Oka Shinichi
Аннотация
OBJECTIVE: To evaluate effect of recombinant human growth hormone (rhGH) among HIV-infected adults with moderate to severe facial lipoatrophy as a side effect of long-term antiretroviral treatment.
DESIGN: A prospective open-label study
METHODS: Twenty-five HIV-1 patients with moderate to severe facial lipoatrophy who had been on antiretroviral treatment for more than 18 months were enrolled. rhGH (5 mg) was given every other day for 6 months. After treatment was completed, the participants were followed up for 6 months. Facial lipoatrophy was evaluated by computed tomography at months 0, 3, 6 and 12.
RESULTS: Nearly all participants (24 of 25) completed the study. The sum of bilateral soft tissue thickness at the level of zygomatics at months 0, 3, 6, 12 were 7.23, 8.59, 8.35, 8.60 mm, respectively. There was significant improvement from baseline in month 3 (p=0.009) and month 12 (p=0.021). In the 6 months of follow-up, the soft tissue showed no significant decrease. Several side effects including diarrhea, arthralgia, myalgia, mastalgia and hand numbness were seen, which were self-limited and transient.
CONCLUSION: rhGH is effective and relatively safe for moderate to severe facial lipoatrophy. Its effect was sustained at least for 6 months after the cessation of rhGH.
DESIGN: A prospective open-label study
METHODS: Twenty-five HIV-1 patients with moderate to severe facial lipoatrophy who had been on antiretroviral treatment for more than 18 months were enrolled. rhGH (5 mg) was given every other day for 6 months. After treatment was completed, the participants were followed up for 6 months. Facial lipoatrophy was evaluated by computed tomography at months 0, 3, 6 and 12.
RESULTS: Nearly all participants (24 of 25) completed the study. The sum of bilateral soft tissue thickness at the level of zygomatics at months 0, 3, 6, 12 were 7.23, 8.59, 8.35, 8.60 mm, respectively. There was significant improvement from baseline in month 3 (p=0.009) and month 12 (p=0.021). In the 6 months of follow-up, the soft tissue showed no significant decrease. Several side effects including diarrhea, arthralgia, myalgia, mastalgia and hand numbness were seen, which were self-limited and transient.
CONCLUSION: rhGH is effective and relatively safe for moderate to severe facial lipoatrophy. Its effect was sustained at least for 6 months after the cessation of rhGH.
Предметные рубрики MeSH
AdultAgedAnalysis of VarianceAntiretroviral Therapy, Highly ActiveDose-Response Relationship, DrugDrug Administration ScheduleDrug Therapy, CombinationEstheticsFemaleFollow-Up StudiesGrowth HormoneHIV-Associated Lipodystrophy SyndromeHumansInjections, SubcutaneousMaleMiddle AgedPilot ProjectsProbabilityProspective StudiesQuality of LifeRisk AssessmentSeverity of Illness IndexSingle-Blind MethodTreatment Outcome